

Accepted Manuscript

Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)

Anne S. Tsao, MD, James Moon, MS, Ignacio I. Wistuba, MD, Nicholas J. Vogelzang, MD, Gregory P. Kalemkerian, MD, Mary W. Redman, PhD, David R. Gandara, MD, Karen Kelly, MD

PII: S1556-0864(17)30429-X

DOI: [10.1016/j.jtho.2017.05.021](https://doi.org/10.1016/j.jtho.2017.05.021)

Reference: JTHO 608

To appear in: *Journal of Thoracic Oncology*

Received Date: 10 March 2017

Revised Date: 3 May 2017

Accepted Date: 4 May 2017

Please cite this article as: Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K, Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905), *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2017.05.021.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)

Anne S. Tsao, MD¹, James Moon, MS², Ignacio I. Wistuba, MD³, Nicholas J. Vogelzang, MD⁴, Gregory P. Kalemkerian, MD⁵, Mary W. Redman, PhD², David R. Gandara, MD⁶, Karen Kelly, MD⁶

¹University of Texas M.D. Anderson Cancer Center Department of Thoracic & Head and Neck Medical Oncology, Houston, TX; ²SWOG Statistical Center, Seattle, WA; ³University of Texas M.D. Anderson Cancer Center Department of Translational Molecular Pathology, ⁴Comprehensive Cancer Centers of Nevada, Las Vegas, NV; ⁵University of Michigan, Ann Arbor, MI; ⁶UC Davis Cancer Center, Sacramento, CA

Key words: mesothelioma, cediranib, cisplatin, pemetrexed

ClinicalTrials.gov Identifier: NCT01064648

Funding: This work was supported by the National Institutes of Health, National Cancer Institute grant numbers CA180888, CA180819, CA180858, CA180801 and CA180846

Corresponding author: Anne S. Tsao, MD

Department of Thoracic & Head and Neck Medical Oncology, Unit 432
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
Phone: 713-792-6363
Fax: 713-792-1220
Email: astsao@mdanderson.org

Download English Version:

<https://daneshyari.com/en/article/5701529>

Download Persian Version:

<https://daneshyari.com/article/5701529>

[Daneshyari.com](https://daneshyari.com)